Program
polfurmetinib
Also written as “Oral [14C] PF-07799544”, “Oral Unlabeled PF-07799544” and “IV [14C] PF-07799544”.
In Pfizer's pipeline, MEK brain penetrant inhibitor
. Its studies are mostly in Melanoma, led by Pfizer.
Furthest: phase 1, since Sep 9, 20223 company-led studies, 1 open or runningNext primary completion: Aug 31, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 31 open or running | phase 1since Sep 9, 2022 | Sep 9, 2022 | Aug 31, 2027phase 1 · NCT05538130 |
- Named in Pfizer’s own pipeline as
polfurmetinib PF-07799544
, phase 1, as of Nov 3, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 9, 2022First study: phase 1 study in MelanomaFirst studyNCT05538130 · 148 enrolled · United States, Australia, Brazil and more
- Apr 6, 2026Phase 1 study in HealthyNCT07563894 · 16 enrolled · United States
- May 5, 2026Phase 1 study in Healthy Male VolunteersNCT07578636 · 9 enrolled · United States
Ahead
- Aug 31, 2027Primary completion: phase 1 study in MelanomaNCT05538130
TargetBeta
“MEK brain penetrant inhibitor”the company's pipeline, read by Claude · source
“An orally bioavailable, brain penetrating inhibitor of mitogen-activated protein kinase kinase (MAP2K; MAPKK; MEK), with potential antineoplastic activity. Upon oral administration, polfurmetinib specifically targets, binds to and inhibits the catalytic activity of MEK, thereby inhibiting the act…”NCIt, read by Claude
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| cobimetinibrule | Hoffmann-La Roche | phase 3 | 38 |
| pimasertibrule | Merck KGaA, Darmstadt, Germany | phase 2 | 13 |
| mirdametinibrule | Merck KGaA, Darmstadt, Germany | phase 2 | 9 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07578636Healthy Male Volunteers · United States | 1 | Completed | Jul 2, 2026 | 9 |
| NCT07563894Healthy · United States | 1 | Completed | Jun 24, 2026 | 16 |
| NCT05538130Melanoma · United States, Australia, Brazil and more | 1 | Active, not recruiting | Aug 31, 2027 | 148 |
How it is read
Names in the registry
- “Oral [14C] PF-07799544”, 1 entry
- “Oral Unlabeled PF-07799544”, 1 entry
- “IV [14C] PF-07799544”, 1 entry
- “PF-07799544”, 1 entry
- “PF-07799933 tablets with PF-07799544 fasted”, 1 entry
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.